Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opko Health Inc (OPK)

Opko Health Inc (OPK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 928,918
  • Shares Outstanding, K 767,701
  • Annual Sales, $ 713,140 K
  • Annual Income, $ -53,220 K
  • EBIT $ -33 M
  • EBITDA $ 67 M
  • 60-Month Beta 1.47
  • Price/Sales 1.37
  • Price/Cash Flow 18.17
  • Price/Book 0.74

Options Overview Details

View History
  • Implied Volatility 166.40% (-23.71%)
  • Historical Volatility 34.42%
  • IV Percentile 86%
  • IV Rank 41.81%
  • IV High 323.62% on 10/13/25
  • IV Low 53.43% on 08/22/25
  • Expected Move (DTE 7) 0.2550 (20.32%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 865
  • Volume Avg (30-Day) 363
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 27,187
  • Open Int (30-Day) 30,540
  • Expected Range 1.0000 to 1.5100

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.09
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +4.58%
on 02/12/26
1.4300 -12.24%
on 01/22/26
-0.0850 (-6.34%)
since 01/13/26
3-Month
1.2000 +4.58%
on 02/12/26
1.4300 -12.24%
on 01/22/26
-0.0250 (-1.95%)
since 11/13/25
52-Week
1.1100 +13.06%
on 08/01/25
2.0350 -38.33%
on 03/05/25
-0.4050 (-24.40%)
since 02/13/25

Most Recent Stories

More News
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the...

OPK : 1.2300 (+1.65%)
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

This is the third  program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have...

OPK : 1.2300 (+1.65%)
ENTX : 1.5070 (-0.86%)
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44 th Annual J.P. Morgan Healthcare Conference, being held January...

OPK : 1.2300 (+1.65%)
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37 th Annual Healthcare Conference, being held December...

OPK : 1.2300 (+1.65%)
NextPlat Reports Third Quarter 2025 Results

Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 

BABA : 155.90 (-1.78%)
NXPL : 0.5655 (-1.67%)
NXPLW : 0.0767 (+0.13%)
OPK : 1.2300 (+1.65%)
OPKO Health: Q3 Earnings Snapshot

OPKO Health: Q3 Earnings Snapshot

OPK : 1.2300 (+1.65%)
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights...

OPK : 1.2300 (+1.65%)
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29,...

OPK : 1.2300 (+1.65%)
REGN : 803.08 (+2.48%)
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ...

OPK : 1.2300 (+1.65%)
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the...

OPK : 1.2300 (+1.65%)

Business Summary

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and...

See More

Key Turning Points

3rd Resistance Point 1.2900
2nd Resistance Point 1.2700
1st Resistance Point 1.2400
Last Price 1.2300
1st Support Level 1.1900
2nd Support Level 1.1700
3rd Support Level 1.1400

See More

52-Week High 2.0350
Fibonacci 61.8% 1.6817
Fibonacci 50% 1.5725
Fibonacci 38.2% 1.4634
Last Price 1.2300
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar